Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19

• Published in: Clinical and experimental medicine 2023-10, Vol.23 (6), p.2739-2748
• Main Authors: Arvanitis, Panos, Lerner, Alexis Hope, Vieira, Kendra, Almaghlouth, Nouf, Farmakiotis, Dimitrios
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - therapeutic use; Cancer; Clinical trials; Comorbidity; Coronaviruses; COVID-19; Hematology; Hospitalization; Humans; Internal Medicine; Malignancy; Medicine; Medicine & Public Health; Metastases; Middle Aged; Monoclonal antibodies; Morbidity; Mortality; Neoplasms - drug therapy; Oncology; Outpatients; Patients; Solid tumors
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-023-01019-y

Patients with cancer have many comorbidities that increase their risk of death from Coronavirus disease 2019 (COVID-19). Anti-spike monoclonal antibodies (mAbs) reduce the risk of hospitalization or death from COVID-19 in the general population. To our knowledge, no studies have focused on the clinical efficacy of mAbs compared to no outpatient treatment exclusively among patients with solid tumors and hematologic malignancies, who are often excluded from clinical trials. We studied patients with cancer who had COVID-19 between 11.9.2020 and 7.21.2022 and received mAbs in an outpatient setting. We compared hospitalization and mortality rates to those of patients with cancer concurrently diagnosed with COVID-19, who were eligible for mAbs, but did not receive any outpatient treatment. 63 patients received mAbs and 89 no outpatient treatment. Administration of mAbs was associated with lower 90-day hospitalization (20.6% vs. 60.7%, p